- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novo Nordisk A/S (NVO)
Novo Nordisk A/S stock price live, this page displays NYSE NVO stock exchange data. View the NVO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novo Nordisk A/S real time stock price chart below.
What Is the Novo Nordisk A/S Stock Price Today?
The Novo Nordisk A/S stock price today is 64.37.
What Is the Stock Symbol for Novo Nordisk A/S?
The stock symbol for Novo Nordisk A/S is ""NVO.""
What Stock Exchange Does Novo Nordisk A/S Trade On?
Novo Nordisk A/S is listed and trades on the NYSE stock exchange.
Is Novo Nordisk A/S a Good Stock to Buy?
Determining whether Novo Nordisk A/S—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVO quote. (ISIN: US6701002056)
What Is the Novo Nordisk A/S Stock Price Today?
The Novo Nordisk A/S stock price today is 64.37.
What Is the Stock Symbol for Novo Nordisk A/S?
The stock symbol for Novo Nordisk A/S is ""NVO.""
What Stock Exchange Does Novo Nordisk A/S Trade On?
Novo Nordisk A/S is listed and trades on the NYSE stock exchange.
Is Novo Nordisk A/S a Good Stock to Buy?
Determining whether Novo Nordisk A/S—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVO quote. (ISIN: US6701002056)
64.37
-1.78(-2.69%)
Closed·
After Hours
63.94-0.43(-0.67%)
·
Fair Value
An estimate of a Novo Nordisk ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.13
64.70
52 wk Range
57.00
148.15
NVO Scorecard
Full Analysis
Has raised its dividend for 7 consecutive years
NVO is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Novo Nordisk ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.1364.70
52 wk Range
57.00148.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.84%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.84%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Novo Nordisk ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
89.67
Upside
+39.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S SWOT Analysis
Metabolic Dominance | Novo Nordisk leads the GLP-1 receptor agonist market with an 85% gross profit margin, showcasing its strength in diabetes and obesity treatments |
Financial Fortitude | Strong 2025 outlook with projected revenue growth of 19-27% and operating profit growth of 24-31%, surpassing consensus expectations |
Innovation Pipeline | Explore Novo Nordisk's next-generation assets like CagriSema and oral Amycretin, poised to revolutionize metabolic disorder treatments |
Market Dynamics | Analysts set price targets ranging from $105 to $160, reflecting confidence in Novo Nordisk's ability to navigate intensifying competition |
Novo Nordisk A/S Earnings Call Summary for Q3/2024
- Q3 2024: Sales up 24%, operating profit up 22%; GLP-1 treatments reach 43M+ patients; carbon emissions rise 34% due to higher capex
- North America ops grow 31%, international 15%; Wegovy sales surge 77% globally; U.S. weekly prescriptions near 215,000
- 2024 guidance: Sales growth 23-27%, operating profit growth 21-27%; Capex forecast at DKK 45B for production expansion
- R&D advancements: Positive trial results for oral semaglutide; regulatory filings expected early 2025
- Catalent acquisition to close end-2024; 2025 sales growth projected in high teens; strong market share in GLP-1 treatments anticipated
Last Updated: 06/11/2024, 22:12
Read Full TranscriptCompare NVO to Peers and Sector
Metrics to compare | NVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 18.1x | 16.7x | −0.5x | |
PEG Ratio | 1.01 | −0.01 | 0.00 | |
Price/Book | 13.7x | 3.5x | 2.6x | |
Price / LTM Sales | 6.2x | 2.8x | 3.0x | |
Upside (Analyst Target) | 37.9% | 17.7% | 54.1% | |
Fair Value Upside | Unlock | 19.7% | 8.7% | Unlock |
Analyst Ratings
6 Buy
4 Hold
2 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 89.67
(+39.30% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
6.53 / 0.8941
Revenue / Forecast
78.09B / 11.38B
People Also Watch
FAQ
What Stock Exchange Does Novo Nordisk ADR Trade On?
Novo Nordisk ADR is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Novo Nordisk ADR?
The stock symbol for Novo Nordisk ADR is "NVO."
What Is the Novo Nordisk ADR Market Cap?
As of today, Novo Nordisk ADR market cap is 283.83B.
What Is Novo Nordisk ADR's Earnings Per Share (TTM)?
The Novo Nordisk ADR EPS (TTM) is 23.51.
When Is the Next Novo Nordisk ADR Earnings Date?
Novo Nordisk ADR will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is NVO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.